Article(id=1329870736661001206, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.05.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1658764800000, receivedDateStr=2022-07-26, revisedDate=1668700800000, revisedDateStr=2022-11-18, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995491422, onlineDateStr=2026-11-18, pubDate=1683648000000, pubDateStr=2023-05-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995491422, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995491422, creator=13701087609, updateTime=1794995491422, updator=13701087609, issue=Issue{id=1329870676980248727, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='5', pageStart='397', pageEnd='520', issueExtLink='null', onlineDate='null', pubDate='1683648000000', pubDateStr='2023-05-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995477194, creator='13701087609', updateTime=1794995882565, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329872377695023554, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329872377695023555, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329870676980248727, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=506, endPage=512, ext={EN=ArticleExt(id=1329870736900076535, articleId=1329870736661001206, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer, columnId=1325221089055486019, journalTitle=World Clinical Drug, columnName=Article, runingTitle=null, highlight=null, articleAbstract=
Objective

To evaluate the efficacy of osimertinib mesylate in the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) by Meta analysis.

Methods

The literature of randomized controlled trial (RCT) of osimertinib mesylate in the treatment of EGFR mutant NSCLC published in the well-known domestic and foreign databases from the establishment of the database to May 2022 were included, and RevMan5.2 software was used to perform meta-analysis on its effect.

Results

A total of 7 articles were included, including 2 reports in Chinese and 5 reports in English, with a total of 2 591 patients. There were 1 385 cases in the experiment group treated with osimertinib mesylate and 1 206 cases in the control group treated with chemotherapy or gefitinib or erlotinib. The quality of the included articles was up to the standard. The literature on clinical benefit rate and total effective rate was heterogeneous (I2=62%, P=0.02; I2=65%, P=0.04). Random effects model analysis showed no significant difference (RR=0.08, 95%CI: -0.12 -0.14, P=0.159; RR=0.04, 95%CI: -0.02 - 0.11, P=0.136). There were no heterogeneity in progression free survival (PSF), overall survival (OS), survival, and median duration of remission (mDOR, I2=41%, P=0.26; I2=36%, P=0.31; I2=25%, P=0.63; I2=18%, P=0.72). The PSF, OS and mDOR in the experiment group were longer than those in the control group (WMD=4.38, 95%CI: 4.25 - 4.46, P<0.001; WMD=3.97, 95%CI: 3.82 - 4.09, P<0.001; WMD=3.36, 95%CI: 3.14~3.58, P<0.001), and the survival rate of the experiment group was higher than that of the control group (WMD=2.57, 95%CI: 2.25 - 2.7, P<0.001). There was no risk of publication bias.

Conclusion

Compared with chemotherapy or gefitinib or erlotinib, osimertinib mesylate can prolong PSF, OS, mDOR and improve survival rate in patients with EGFR mutant NSCLC.

, authors=Huili HE1, Haiwei ZHANG2, Dongdong YUAN3, Mengxing LIU4, *, authorsList=Huili HE, Haiwei ZHANG, Dongdong YUAN, Mengxing LIU, authorCompany=null, correspAuthors=Mengxing LIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329870737218843640, articleId=1329870736661001206, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=甲磺酸奥希替尼治疗EGFR突变型非小细胞肺癌的效果meta分析, columnId=1325221089235841093, journalTitle=世界临床药物, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=
目的

对甲磺酸奥希替尼治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)突变型非小细胞肺癌(non small cell lung cancer,NSCLC)的效果进行meta分析。

方法

纳入国内外各数据库从建库至2022年5月公开发表的甲磺酸奥希替尼治疗EGFR突变型NSCLC随机对照试验(randomized controlled trial,RCT)文献,采用RevMan5.2软件对其效果实施meta分析。

结果

共纳入7篇文献,其中2篇中文报道,5篇英文报道,共2 591例患者;甲磺酸奥希替尼治疗的试验组共1 385例,采用化疗或吉非替尼或厄洛替尼治疗的对照组共1 206例,纳入的文献质量均达标;临床获益率、总有效率文献有异质性(I2=62%、P=0.02;I2=65%、P=0.04)随机效应模型分析,差异无统计学意义(RR=0.08,95%CI:-0.12~0.14,P=0.159;RR=0.04,95%CI:-0.02~0.11,P=0.136);无进展生存期(progression free survival,PSF)、总生存期(overall survival,OS)、生存率、中位缓解持续时间(median duration of remission,mDOR)文献无异质性(I2=41%、P=0.26;I2=36%、P=0.31;I2=25%、P=0.63;I2=18%、P=0.72),试验组PSF、OS、mDOR均较对照组延长(WMD=4.38,95%CI:4.25~4.46,P<0.001;WMD=3.97,95%CI:3.82~4.09,P<0.001;WMD=3.36,95%CI:3.14~3.58,P<0.001),且试验组生存率较对照组高(WMD=2.57,95%CI:2.25~2.78,P<0.001),均未见发表偏倚风险。

结论

与化疗或吉非替尼或厄洛替尼治疗相比,甲磺酸奥希替尼治疗EGFR突变型NSCLC患者可延长PSF、OS及mDOR,提高生存率。

, authors=何慧丽1, 张海伟2, 袁冬冬3, 刘孟兴4, *, authorsList=何慧丽, 张海伟, 袁冬冬, 刘孟兴, authorCompany=null, correspAuthors=刘孟兴, authorNote=

何慧丽,主管药师,研究方向:临床药学。

, correspAuthorsNote=
刘孟兴,主任药师,研究方向:医院药学。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=F5uyt/WKFcn+yzBhZQAdYg==, magXml=H+zpSLJgTqjNVQT3NifArw==, pdfUrl=null, pdf=iXtXwhnbJRoM5TCtDDiFrg==, pdfFileSize=1771951, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=9YIUNHJ66ugNPAK1z1JNBg==, mapNumber=null, fund=null)}, authors=[Author(id=1329870737772490757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870737868959751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870737772490757, language=EN, stringName=Huili HE, firstName=Huili, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870737936068616, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870737772490757, language=CN, stringName=何慧丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.安阳市肿瘤医院药学部,河南 安阳 455001, bio={"content":"

何慧丽,主管药师,研究方向:临床药学。

"}, bioImg=null, bioContent=

何慧丽,主管药师,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737415975929, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=1., ext=[AuthorCompanyExt(id=1329870737424364538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737428558843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.安阳市肿瘤医院药学部,河南 安阳 455001)])]), Author(id=1329870738003177482, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870738078674957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738003177482, language=EN, stringName=Haiwei ZHANG, firstName=Haiwei, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738158366734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738003177482, language=CN, stringName=张海伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737491473404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=2., ext=[AuthorCompanyExt(id=1329870737499862013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329870737508250622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099)])]), Author(id=1329870738254835728, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870738380664850, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738254835728, language=EN, stringName=Dongdong YUAN, firstName=Dongdong, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738468745235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738254835728, language=CN, stringName=袁冬冬, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737608913919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=3., ext=[AuthorCompanyExt(id=1329870737617302528, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737621495808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)])]), Author(id=1329870738548437013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870738619740183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738548437013, language=EN, stringName=Mengxing LIU, firstName=Mengxing, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738691043352, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738548437013, language=CN, stringName=刘孟兴, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737688604673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=4., ext=[AuthorCompanyExt(id=1329870737696993282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737701187587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)])])], keywords=[Keyword(id=1329870738779123737, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=EN, orderNo=1, keyword=osimertinib mesylate), Keyword(id=1329870738833649690, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=EN, orderNo=2, keyword=epidermal growth factor receptor), Keyword(id=1329870738888175643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=EN, orderNo=3, keyword=non small cell lung cancer), Keyword(id=1329870738955284508, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=CN, orderNo=1, keyword=甲磺酸奥希替尼), Keyword(id=1329870739022393373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=CN, orderNo=2, keyword=表皮生长因子受体), Keyword(id=1329870739106279454, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, language=CN, orderNo=3, keyword=非小细胞肺癌)], refs=[Reference(id=1329870739278245920, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy[J]. Ann Oncol, 2021, 32(6): 698-709., articleTitle=null, refAbstract=null), Reference(id=1329870739341160481, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=常鹄, 田古, 黄慧瑶, 等. 亚太经合组织7个经济体肺癌防控的调查分析与研究[J]. 中国肿瘤, 2020, 29(6): 401-410., articleTitle=null, refAbstract=null), Reference(id=1329870739404075042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=胡明明, 阳苑, 张同梅, 等. 7843例原发肺恶性肿瘤流行病学特征分析[J]. 现代肿瘤医学, 2021, 29(4): 682-685., articleTitle=null, refAbstract=null), Reference(id=1329870739466989603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723., articleTitle=null, refAbstract=null), Reference(id=1329870739525709860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score≥50[J]. J Clin Oncol, 2021, 39(21): 2339-2349., articleTitle=null, refAbstract=null), Reference(id=1329870739584430117, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21(3): 373-386., articleTitle=null, refAbstract=null), Reference(id=1329870739651538982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer[J]. Cancer, 2020, 126(2): 373-380., articleTitle=null, refAbstract=null), Reference(id=1329870739735425064, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis[J]. Ann Oncol, 2020, 31(11): 1536-1544., articleTitle=null, refAbstract=null), Reference(id=1329870739819311145, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=王洁, 皮灿. 奥希替尼与培美曲塞联合铂类化疗在EGFR T790M阳性非小细胞肺癌患者中的疗效比较[J]. 循证医学, 2018, 18(1): 36-39., articleTitle=null, refAbstract=null), Reference(id=1329870740003860522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125., articleTitle=null, refAbstract=null), Reference(id=1329870740070969387, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Wu YL, Herbst RS, Mann H, et al. ADAURA: phase Ⅲ, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection[J]. Clin Lung Cancer, 2018, 19(4): e533-e536., articleTitle=null, refAbstract=null), Reference(id=1329870740129689644, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=王如坤, 张振亮, 邱斌, 等. 奥希替尼治疗EGFR T790M阳性非小细胞肺癌的临床疗效[J]. 临床肺科杂志, 2019, 24(7): 1257-1260., articleTitle=null, refAbstract=null), Reference(id=1329870740268101677, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset[J]. Jpn J Clin Oncol, 2019, 49(1): 29-36., articleTitle=null, refAbstract=null), Reference(id=1329870740351987759, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheng Y, He Y, Li W, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study[J]. Target Oncol, 2021, 16(2): 165-176., articleTitle=null, refAbstract=null), Reference(id=1329870740419096624, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC[J]. Target Oncol, 2021, 16(5): 687-695., articleTitle=null, refAbstract=null), Reference(id=1329870740486205489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2020, 382(1): 41-50., articleTitle=null, refAbstract=null), Reference(id=1329870740570091570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phaseⅠb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020, 31(4): 507-516., articleTitle=null, refAbstract=null), Reference(id=1329870740633006131, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations[J]. J Thorac Oncol, 2021, 16(5): 764-773., articleTitle=null, refAbstract=null), Reference(id=1329870740721086516, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Hochmair MJ, Morabito A, Hao D, et al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study[J]. Future Oncol, 2020, 16(34): 2799-2808., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329870739194359839, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, awardId=61702164, language=CN, fundingSource=国家自然科学基金项目(61702164), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329870737415975929, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=1., ext=[AuthorCompanyExt(id=1329870737424364538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737428558843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.安阳市肿瘤医院药学部,河南 安阳 455001)]), AuthorCompany(id=1329870737491473404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=2., ext=[AuthorCompanyExt(id=1329870737499862013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329870737508250622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099)]), AuthorCompany(id=1329870737608913919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=3., ext=[AuthorCompanyExt(id=1329870737617302528, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737621495808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)]), AuthorCompany(id=1329870737688604673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=4., ext=[AuthorCompanyExt(id=1329870737696993282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737701187587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.05.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.05.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.05.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.05.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1683648000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
甲磺酸奥希替尼治疗EGFR突变型非小细胞肺癌的效果meta分析
何慧丽 1 , 张海伟 2 , 袁冬冬 3 , 刘孟兴 4, *
世界临床药物 | 研究论文 2023,44(5): 506-512
收起
收藏切换
世界临床药物 |研究论文 2023 , 44 (5) : 506 -512
甲磺酸奥希替尼治疗EGFR突变型非小细胞肺癌的效果meta分析
全屏
[Author(id=1329870737772490757, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870737868959751, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870737772490757, language=EN, stringName=Huili HE, firstName=Huili, middleName=null, lastName=HE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870737936068616, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870737772490757, language=CN, stringName=何慧丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.安阳市肿瘤医院药学部,河南 安阳 455001, bio={"content":"

何慧丽,主管药师,研究方向:临床药学。

"}, bioImg=null, bioContent=

何慧丽,主管药师,研究方向:临床药学。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737415975929, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=1., ext=[AuthorCompanyExt(id=1329870737424364538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737428558843, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737415975929, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.安阳市肿瘤医院药学部,河南 安阳 455001)])]), Author(id=1329870738003177482, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870738078674957, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738003177482, language=EN, stringName=Haiwei ZHANG, firstName=Haiwei, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738158366734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738003177482, language=CN, stringName=张海伟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737491473404, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=2., ext=[AuthorCompanyExt(id=1329870737499862013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329870737508250622, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737491473404, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099)])]), Author(id=1329870738254835728, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329870738380664850, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738254835728, language=EN, stringName=Dongdong YUAN, firstName=Dongdong, middleName=null, lastName=YUAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738468745235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738254835728, language=CN, stringName=袁冬冬, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=3, address=3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737608913919, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=3., ext=[AuthorCompanyExt(id=1329870737617302528, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737621495808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737608913919, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)])]), Author(id=1329870738548437013, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329870738619740183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738548437013, language=EN, stringName=Mengxing LIU, firstName=Mengxing, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329870738691043352, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, authorId=1329870738548437013, language=CN, stringName=刘孟兴, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329870737688604673, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, xref=4., ext=[AuthorCompanyExt(id=1329870737696993282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China), AuthorCompanyExt(id=1329870737701187587, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329870736661001206, companyId=1329870737688604673, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001)])])]
何慧丽1, 张海伟2, 袁冬冬3, 刘孟兴4, *
作者信息
  • 1.安阳市肿瘤医院药学部,河南 安阳 455001
  • 2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099
  • 3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001
  • 4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001
通讯作者:
刘孟兴,主任药师,研究方向:医院药学。
作者简介:

何慧丽,主管药师,研究方向:临床药学。

Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer
Huili HE1, Haiwei ZHANG2, Dongdong YUAN3, Mengxing LIU4, *
Affiliations
  • 1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
  • 2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China
  • 3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
  • 4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
出版时间: 2023-05-10 doi: 10.13683/j.wph.2023.05.017
文章导航
收藏切换
目的

对甲磺酸奥希替尼治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)突变型非小细胞肺癌(non small cell lung cancer,NSCLC)的效果进行meta分析。

方法

纳入国内外各数据库从建库至2022年5月公开发表的甲磺酸奥希替尼治疗EGFR突变型NSCLC随机对照试验(randomized controlled trial,RCT)文献,采用RevMan5.2软件对其效果实施meta分析。

结果

共纳入7篇文献,其中2篇中文报道,5篇英文报道,共2 591例患者;甲磺酸奥希替尼治疗的试验组共1 385例,采用化疗或吉非替尼或厄洛替尼治疗的对照组共1 206例,纳入的文献质量均达标;临床获益率、总有效率文献有异质性(I2=62%、P=0.02;I2=65%、P=0.04)随机效应模型分析,差异无统计学意义(RR=0.08,95%CI:-0.12~0.14,P=0.159;RR=0.04,95%CI:-0.02~0.11,P=0.136);无进展生存期(progression free survival,PSF)、总生存期(overall survival,OS)、生存率、中位缓解持续时间(median duration of remission,mDOR)文献无异质性(I2=41%、P=0.26;I2=36%、P=0.31;I2=25%、P=0.63;I2=18%、P=0.72),试验组PSF、OS、mDOR均较对照组延长(WMD=4.38,95%CI:4.25~4.46,P<0.001;WMD=3.97,95%CI:3.82~4.09,P<0.001;WMD=3.36,95%CI:3.14~3.58,P<0.001),且试验组生存率较对照组高(WMD=2.57,95%CI:2.25~2.78,P<0.001),均未见发表偏倚风险。

结论

与化疗或吉非替尼或厄洛替尼治疗相比,甲磺酸奥希替尼治疗EGFR突变型NSCLC患者可延长PSF、OS及mDOR,提高生存率。

甲磺酸奥希替尼  /  表皮生长因子受体  /  非小细胞肺癌
Objective

To evaluate the efficacy of osimertinib mesylate in the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) by Meta analysis.

Methods

The literature of randomized controlled trial (RCT) of osimertinib mesylate in the treatment of EGFR mutant NSCLC published in the well-known domestic and foreign databases from the establishment of the database to May 2022 were included, and RevMan5.2 software was used to perform meta-analysis on its effect.

Results

A total of 7 articles were included, including 2 reports in Chinese and 5 reports in English, with a total of 2 591 patients. There were 1 385 cases in the experiment group treated with osimertinib mesylate and 1 206 cases in the control group treated with chemotherapy or gefitinib or erlotinib. The quality of the included articles was up to the standard. The literature on clinical benefit rate and total effective rate was heterogeneous (I2=62%, P=0.02; I2=65%, P=0.04). Random effects model analysis showed no significant difference (RR=0.08, 95%CI: -0.12 -0.14, P=0.159; RR=0.04, 95%CI: -0.02 - 0.11, P=0.136). There were no heterogeneity in progression free survival (PSF), overall survival (OS), survival, and median duration of remission (mDOR, I2=41%, P=0.26; I2=36%, P=0.31; I2=25%, P=0.63; I2=18%, P=0.72). The PSF, OS and mDOR in the experiment group were longer than those in the control group (WMD=4.38, 95%CI: 4.25 - 4.46, P<0.001; WMD=3.97, 95%CI: 3.82 - 4.09, P<0.001; WMD=3.36, 95%CI: 3.14~3.58, P<0.001), and the survival rate of the experiment group was higher than that of the control group (WMD=2.57, 95%CI: 2.25 - 2.7, P<0.001). There was no risk of publication bias.

Conclusion

Compared with chemotherapy or gefitinib or erlotinib, osimertinib mesylate can prolong PSF, OS, mDOR and improve survival rate in patients with EGFR mutant NSCLC.

osimertinib mesylate  /  epidermal growth factor receptor  /  non small cell lung cancer
何慧丽, 张海伟, 袁冬冬, 刘孟兴. 甲磺酸奥希替尼治疗EGFR突变型非小细胞肺癌的效果meta分析. 世界临床药物, 2023 , 44 (5) : 506 -512 . DOI: 10.13683/j.wph.2023.05.017
Huili HE, Haiwei ZHANG, Dongdong YUAN, Mengxing LIU. Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer[J]. World Clinical Drug, 2023 , 44 (5) : 506 -512 . DOI: 10.13683/j.wph.2023.05.017
  • 国家自然科学基金项目(61702164)
参考文献 引证文献
排序方式:
[1]
Remon J, Aldea M, Besse B, et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy[J]. Ann Oncol, 2021, 32(6): 698-709.
[2]
常鹄, 田古, 黄慧瑶, 等. 亚太经合组织7个经济体肺癌防控的调查分析与研究[J]. 中国肿瘤, 2020, 29(6): 401-410.
[3]
胡明明, 阳苑, 张同梅, 等. 7843例原发肺恶性肿瘤流行病学特征分析[J]. 现代肿瘤医学, 2021, 29(4): 682-685.
[4]
Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
[5]
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score≥50[J]. J Clin Oncol, 2021, 39(21): 2339-2349.
[6]
Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21(3): 373-386.
[7]
Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer[J]. Cancer, 2020, 126(2): 373-380.
[8]
Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis[J]. Ann Oncol, 2020, 31(11): 1536-1544.
[9]
王洁, 皮灿. 奥希替尼与培美曲塞联合铂类化疗在EGFR T790M阳性非小细胞肺癌患者中的疗效比较[J]. 循证医学, 2018, 18(1): 36-39.
[10]
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
[11]
Wu YL, Herbst RS, Mann H, et al. ADAURA: phase Ⅲ, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection[J]. Clin Lung Cancer, 2018, 19(4): e533-e536.
[12]
王如坤, 张振亮, 邱斌, 等. 奥希替尼治疗EGFR T790M阳性非小细胞肺癌的临床疗效[J]. 临床肺科杂志, 2019, 24(7): 1257-1260.
[13]
Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset[J]. Jpn J Clin Oncol, 2019, 49(1): 29-36.
[14]
Cheng Y, He Y, Li W, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study[J]. Target Oncol, 2021, 16(2): 165-176.
[15]
Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC[J]. Target Oncol, 2021, 16(5): 687-695.
[16]
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2020, 382(1): 41-50.
[17]
Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phaseⅠb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer[J]. Ann Oncol, 2020, 31(4): 507-516.
[18]
Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations[J]. J Thorac Oncol, 2021, 16(5): 764-773.
[19]
Hochmair MJ, Morabito A, Hao D, et al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study[J]. Future Oncol, 2020, 16(34): 2799-2808.
2023年第44卷第5期
9
1
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.05.017
  • 接收时间:2022-07-26
  • 首发时间:2026-11-18
  • 出版时间:2023-05-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-07-26
  • 修回日期:2022-11-18
基金
国家自然科学基金项目(61702164)
作者信息
    1.安阳市肿瘤医院药学部,河南 安阳 455001
    2.哈密市中心医院药剂科,新疆 维吾尔哈密 839099
    3.安阳市肿瘤医院肿瘤内科;河南 安阳 455001
    4.安阳市肿瘤医院肿瘤内科;河南 安阳 455001

通讯作者:

刘孟兴,主任药师,研究方向:医院药学。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.05.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏